HMG辅酶A还原酶抑制剂（他汀类药物）与主动脉瓣钙化

HMG CoA reductase inhibitor (statin) and aortic valve calcium.

作者信息

Shavelle David M, Takasu Junichuro, Budoff Matthew J, Mao SongShou, Zhao Xue Qiao, O'Brien Kevin D

机构信息

Division of Cardiology, Department of Medicine, University of Washington, Seattle, WA 98195-6422, USA.

出版信息

Lancet. 2002 Mar 30;359(9312):1125-6. doi: 10.1016/S0140-6736(02)08161-8.

DOI:10.1016/S0140-6736(02)08161-8

PMID:11943265

Abstract

There is no known pharmacological therapy for calcific aortic valvular sclerosis or stenosis. Because leaflet calcification occurs in areas of lipoprotein deposition, we hypothesised that 3-hydroxy-3-methylglutaryl-coenzyme A (HMG COA) reductase inhibitors (statins) might slow aortic valve calcium (AVC) accumulation. We retrospectively identified 65 patients who had undergone two electron-beam computed tomography scans at a mean (SD) interval of 2.5 (1.6) years. 28 (43%) patients were receiving statins. Patients who were treated with statins had a 62-63% lower median rate of AVC accumulation (p=0.006) and 44-49% fewer statin patients had definite AVC progression (p=0.043). These findings suggest that statins may decrease AVC accumulation.

摘要

目前尚无针对钙化性主动脉瓣硬化或狭窄的已知药物治疗方法。由于瓣叶钙化发生在脂蛋白沉积区域，我们推测3-羟基-3-甲基戊二酰辅酶A（HMG COA）还原酶抑制剂（他汀类药物）可能会减缓主动脉瓣钙（AVC）的积累。我们回顾性地确定了65例患者，他们平均间隔2.5（1.6）年接受了两次电子束计算机断层扫描。28例（43%）患者正在服用他汀类药物。接受他汀类药物治疗的患者AVC积累的中位数速率降低了62%-63%（p=0.006），并且他汀类药物治疗的患者中明确出现AVC进展的人数减少了44%-49%（p=0.043）。这些发现表明他汀类药物可能会减少AVC的积累。